Abstract
Reactive species are continuously produced in vivo by all body tissues. However, when an imbalance between the reactive species production and the endogenous pool of antioxidants occurs, the resulting oxidative stress can somehow intensify the pathophysiological mechanisms of several diseases, such as neurodegenerative diseases. Although the aetiology of Parkinson’s and Alzheimer’s diseases is not yet completely understood, it is accepted by the scientific community that the oxidative stress can act as a trigger or can be involved in the course of both diseases. Therefore, the development of an antioxidant-based therapy could be a helpful approach to ameliorate the deleterious effects of oxidative stress in neurodegenerative diseases. Coumarins and chromones are natural or synthetic chemical entities described as privileged structures with diverse biological activities that have been used to design new drugs with potential anti-Alzheimer and anti-Parkinson profiles. Since some of these compounds also displayed potent antioxidant activity, the rationale approach to developing new drugs based on the benzopyran scaffold, as therapeutic alternatives for neurodegenerative diseases, is a valid and compelling topic. This review provides a medicinal chemistry overview on the discovery and development of benzopyran-based compounds endowed with antioxidant, neuroprotective and anti-Alzheimer or anti-Parkinson activities.
Keywords: Neurodegenerative diseases, Alzheimer’s disease, Parkinson’s disease, Oxidative stress, Chromones, Coumarins.
Current Topics in Medicinal Chemistry
Title:Oxidative Stress and Neurodegenerative Diseases: Looking for a Therapeutic Solution Inspired on Benzopyran Chemistry
Volume: 15 Issue: 5
Author(s): Alexandra Gaspar, Nuno Milhazes, Lourdes Santana, Eugenio Uriarte, Fernanda Borges and Maria Joao Matos
Affiliation:
Keywords: Neurodegenerative diseases, Alzheimer’s disease, Parkinson’s disease, Oxidative stress, Chromones, Coumarins.
Abstract: Reactive species are continuously produced in vivo by all body tissues. However, when an imbalance between the reactive species production and the endogenous pool of antioxidants occurs, the resulting oxidative stress can somehow intensify the pathophysiological mechanisms of several diseases, such as neurodegenerative diseases. Although the aetiology of Parkinson’s and Alzheimer’s diseases is not yet completely understood, it is accepted by the scientific community that the oxidative stress can act as a trigger or can be involved in the course of both diseases. Therefore, the development of an antioxidant-based therapy could be a helpful approach to ameliorate the deleterious effects of oxidative stress in neurodegenerative diseases. Coumarins and chromones are natural or synthetic chemical entities described as privileged structures with diverse biological activities that have been used to design new drugs with potential anti-Alzheimer and anti-Parkinson profiles. Since some of these compounds also displayed potent antioxidant activity, the rationale approach to developing new drugs based on the benzopyran scaffold, as therapeutic alternatives for neurodegenerative diseases, is a valid and compelling topic. This review provides a medicinal chemistry overview on the discovery and development of benzopyran-based compounds endowed with antioxidant, neuroprotective and anti-Alzheimer or anti-Parkinson activities.
Export Options
About this article
Cite this article as:
Gaspar Alexandra, Milhazes Nuno, Santana Lourdes, Uriarte Eugenio, Borges Fernanda and Matos Joao Maria, Oxidative Stress and Neurodegenerative Diseases: Looking for a Therapeutic Solution Inspired on Benzopyran Chemistry, Current Topics in Medicinal Chemistry 2015; 15 (5) . https://dx.doi.org/10.2174/1568026614666141229124141
DOI https://dx.doi.org/10.2174/1568026614666141229124141 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Extrahepatic Metabolism may Complicate the IVIVC in Rats
Drug Metabolism Letters From Cerebrospinal Fluid Pulsation to Noninvasive Intracranial Compliance and Pressure Measured by MRI Flow Studies
Current Medical Imaging Cognitive Improvement by Photic Stimulation in a Mouse Model of Alzheimer’s Disease
Current Alzheimer Research Anti-Degenerative Effect of Melatonin on Intervertebral Disc: Protective Contribution against Inflammation, Oxidative Stress, Apoptosis, and Autophagy
Current Drug Targets REM Sleep Behavior Disorder and Narcolepsy
CNS & Neurological Disorders - Drug Targets ADAM Metalloproteinases as Potential Drug Targets
Current Medicinal Chemistry Peroxisome Proliferator Activated Receptor Gamma Coactivator 1 Alpha: An Emerging Target for Neuroprotection in Parkinson’s Disease
CNS & Neurological Disorders - Drug Targets The Mutual Interaction Between Sleep and Epilepsy on the Neurobiological Basis and Therapy
Current Neuropharmacology Halting Arterial Aging in Patients with Cardiovascular Disease: Hypolipidemic and Antihypertensive Therapy
Current Pharmaceutical Design Quantitative Characterization of Magnetic Mobility of Nanoparticle in Solution-Based Condition
Current Pharmaceutical Design Patent Selections:
Recent Patents on Biomedical Engineering (Discontinued) Structure-Based Drug Design of Peptide Mimetics Containing Large P3 Moieties as Inhibitors of Factor VIIa
Letters in Drug Design & Discovery The GABAA-BZR Complex as Target for the Development of Anxiolytic Drugs
Current Topics in Medicinal Chemistry Hierarchically Organized Nanocomposites Derived from Low-dimensional Nanomaterials for Efficient Removal of Organic Pollutants
Current Organic Chemistry Molecular Mechanisms Triggered by Bile Acids on Intestinal Ca2+ Absorption
Current Medicinal Chemistry New Insights into the Mechanisms of Mitochondrial Preconditioning-Triggered Neuroprotection
Current Pharmaceutical Design DJ-1: A New Comer in Parkinsons Disease Pathology
Current Molecular Medicine Methylenetetrahydrofolate Reductase: Biochemical Characterization and Medical Significance
Current Pharmaceutical Design Editorial [Hot topic: Latest Development on Zinc Enzymes (Executive Editor: Georgios A. Spyroulias)]
Current Pharmaceutical Design Competitive Interaction Between Plasma Omega-3 Fatty Acids and Arachidonic Acid is Related to Down-Regulation of A Signaling Mediator
Medicinal Chemistry